|1.||Pegg, Anthony E: 1 article (04/2002)|
|2.||Sawicki, Janet A: 1 article (04/2002)|
|3.||Shantz, Lisa M: 1 article (04/2002)|
|4.||O'Brien, Thomas G: 1 article (04/2002)|
|5.||Guo, Yongjun: 1 article (04/2002)|
|6.||Kesari, K V: 1 article (09/2000)|
|7.||Colandrea, T D: 1 article (09/2000)|
|8.||D'Armiento, J: 1 article (09/2000)|
|9.||Chada, K K: 1 article (09/2000)|
04/01/2002 - "In experiments utilizing chrysarobin, a tumor promoter with a different mechanism of action than TPA, again there was no significant difference in tumor formation between K6/ODCdn mice and littermate controls. "
03/01/1991 - "The results presented in this paper suggest that there is a common pathway controlling susceptibility to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate, BzPo, and chrysarobin. "
01/01/1989 - "Histologic alterations produced by chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) in SENCAR mouse skin: relationship to skin tumor promoting activity."
08/01/1988 - "In additional experiments, using a once-weekly application of chrysarobin, RA also inhibited skin tumor promotion but the magnitude of inhibition was less. "
08/01/1988 - "Modulation of chrysarobin skin tumor promotion."
11/01/1988 - "While some differences were observed in the properties of ODC from chrysarobin-promoted versus TPA-promoted papillomas, the major conclusion of this study is that both agents cause the appearance of a functionally altered ODC in the majority of papillomas produced by a two-step protocol."
05/01/1996 - "Furthermore, despite its ability to generate free radical intermediates, chrysarobin does not enhance the malignant progression of pre-existing papillomas induced by TPA treatment."
05/01/1996 - "Collectively, the results indicate that papillomas promoted by chrysarobin have growth properties similar to those promoted by TPA under similar experimental conditions. "
05/01/1996 - "Five weeks after the cessation of chrysarobin treatment, the papilloma response reached a maximum of 13.2 papillomas/mouse. "
05/01/1996 - "Regression and progression characteristics of papillomas induced by chrysarobin in SENCAR mice."
|3.||Psoriasis (Pustulosis Palmaris et Plantaris)
08/01/1983 - "Earlier, a natural product, chrysarobin, originally derived from the South American araroba tree, had been used to treat psoriasis. "
01/01/1965 - "PSORIASIS; A STATISTICAL STUDY OF THE GOECKERMAN AND THE CHRYSAROBIN THERAPIES, AND OF VARIOUS FACTORS INFLUENCING THE CLINIC."
01/01/1965 - "[Experimental studies of the mechanism of action of chrysarobin and dithranol in psoriasis (evidence for a cytostatic effect on the epidermis)]."
03/15/1965 - "[Investigations on the mechanism of action of chrysarobin and dithranol (=Cignolin) in psoriasis. "
12/01/1957 - "Chloranil in the treatment of psoriasis; a substitute for chrysarobin."
01/01/1989 - "Twice-weekly applications of chrysarobin for 2.5 weeks induced a moderate hyperplasia, increase in total nucleated epidermal cells, and increased DCs at 48 and 96 h after the last treatment, with a higher value for these parameters occurring at 48 h. "
12/01/1987 - "Chrysarobin (given once-weekly for 4 weeks) induced a moderate sustained hyperplasia and DC response 48 h after the last treatment in both DBA/2 and C57BL/6 mice; however, C57BL/6 mice showed a greater epidermal hyperplasia than DBA/2 mice. "
12/01/1993 - "alpha-TA at the 40 mumol dose also significantly inhibited chrysarobin-induced edema by 22% and epidermal hyperplasia by 17%. "
12/01/1993 - "AP at the 4 mumol dose significantly inhibited the induction of edema by chrysarobin by 24% and the induction of epidermal hyperplasia by 23%. "
01/01/1989 - "Hyperplasia induced by multiple but not single treatments with chrysarobin and TPA correlated quantitatively with their papilloma promoting activity. "
12/15/1988 - "In addition, chrysarobin treatment following 10 wk of TPA promotion did not enhance the progression of preexisting papillomas to carcinomas. "
07/15/1987 - "The progression of papillomas to carcinomas was examined in all chrysarobin-treated groups and compared with three groups of mice treated with 3.4 nmol TPA. "
07/15/1987 - "A similar dose-response relationship for papilloma and carcinoma formation was observed when chrysarobin was applied once weekly. "
06/01/1985 - "Interestingly, at optimal promoting doses, chrysarobin gave a carcinoma response (22% with 0.3 carcinomas per mouse at 45 weeks) similar to that of TPA suggesting that this compound may be more efficient at promoting carcinomas than papillomas. "
|4.||Ornithine Decarboxylase (Decarboxylase, Ornithine)